Stallergenes Greer

25 articles about Stallergenes Greer

• Stallergenes Greer Announces Publication of Positive Results for PALFORZIA® Phase 3 Study in Peanut-allergic Children Aged 1 to 3 Years

  11/20/2023

  Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy (AIT), announces the publication of results from the Phase 3 POSEIDON (Peanut Oral Immunotherapy Study of Early Intervention for Desensitization) study in the New England Journal of Medicine Evidence.

• Stallergenes Greer Showcases Clinical Relevance and Persisting Benefits of Its Allergen Immunotherapy Treatments at 2023 EAACI Congress

  6/9/2023

  Stallergenes Greer, a leading global healthcare company specialising in allergen immunotherapy, will be hosting a company-sponsored symposium entitled “Patient’s perspective: A must have for the future of Allergen Immunotherapy” at the 2023 European Academy of Allergy and Clinical Immunology Congress taking place June 9-11 in Hamburg.

• Stallergenes Greer Foundation to Foster Innovation and Precision Medicine in the Field of Allergy

  4/26/2023

  Stallergenes Greer, a biopharmaceutical company specialising in the research, diagnosis and treatment of respiratory allergies, is pleased to announce its strategic direction for the Stallergenes Greer Foundation.

• Positive Results of EfficAPSI Real-World Study Confirm Significant Benefit of Sublingual Liquid AIT Treatment on the Onset and Worsening of Asthma in Patients With Allergic Rhinitis

  7/2/2022

  Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy, announced positive data from its EfficAPSI real-world study.

• Stallergenes Greer Strengthens Precision Medicine Approach in Allergen Immunotherapy With Imperial College London Research Collaboration

  1/17/2022

  Stallergenes Greer today announced that the company has entered into a research collaboration on the discovery of biomarkers of AIT efficacy with Imperial College London, a global top ten university with a world-class reputation in science, engineering, business and medicine.

• Stallergenes Greer Launches CORAP (Community for Research in Allergic Patients) Research Programme

  10/7/2021

  Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy, announced the launch of CORAP.

• Stallergenes Greer and Alyatec Announce Research Collaboration to Advance Precision Medicine in Allergen Immunotherapy

  7/9/2021

  Stallergenes Greer, a global healthcare company specialising in allergen immunotherapy, and Alyatec, a contract research organisation based in Strasbourg University Hospital, announced that they have entered into a collaboration to advance precision medicine in AIT.

• Stallergenes Greer: Alustal®, the Company’s Subcutaneous Allergen Immunotherapy Treatment (SCIT) Now Available

  6/24/2021

  Stallergenes Greer announces that Alustal®, its subcutaneous allergen immunotherapy (SCIT) solution, is now available in Italy and Spain following the full resumption of SCIT production in Antony (France).

• Positive Outcome of European Decentralised Registration Procedure for Stallergenes Greer’s Sublingual House Dust Mite Allergen Immunotherapy Tablet

  5/31/2021

  Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the positive outcome of the European decentralised registration procedure for its sublingual house dust mite allergen immunotherapy tablet Actair®.

• Stallergenes Greer’s Personalised Allergen Immunotherapy Model Encouraged by Leading Scientists: "Allergy" Journal Publishes Article Today

  9/1/2020

  Stallergenes Greer, a biopharmaceutical company specialising in treatments for allergies, announces the publication of an article titled “Personalized Medicine for allergy treatment: AIT, still a unique and unmatched model” in the EAACI’s (European Academy of Allergy and Clinical Immunology) official journal Allergy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/2

• Stallergenes Greer and Anergis Report Successful Preclinical Study Results With COP-virosomes as Second-generation Allergen Immunotherapy

  5/28/2020

  Stallergenes Greer, a worldwide leader in allergen immunotherapy and Anergis, a leader in ultra-fast AIT research and development, announced the results of a joint research study evaluating the effects of second-generation Contiguous Overlapping Peptides allergen immunotherapy in a therapeutic model of birch pollen allergy, with the aim of shortening AIT administration schemes.

•  Stallergenes Greer: Expands Supply of Subcutaneous Products; Sustains Investment in Quality and Operational Excellence

  5/18/2020

  Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the expansion of the supply of subcutaneous products, further broadening its offering to patients and the medical community through a sustained investment in quality and operational excellence.

• Stallergenes Greer Submits a Marketing Authorisation Application in Europe for Its Sublingual House Dust Mite Allergen Immunotherapy Tablet

  5/4/2020

  Stallergenes Greer, a biopharmaceutical company specialising in treatments for respiratory allergies, announces the submission of a marketing authorisation application for STAGR320, its sublingual house dust mite immunotherapy tablet, via a European decentralized procedure.

• 

  Allergy Immunotherapy: Relief that is Nothing to Sneeze at

  2/27/2020

  *Achoo* Muddling through a stuffy, runny nose and itchy, watery eyes? You aren’t alone -  over 17.6 million American adults (about 7.5%) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as ...

• Stallergenes Greer and Anergis Initiate New Study to Predict Efficacy of Second-Generation Allergen Immunotherapy

  10/17/2019

  Second-generation Allergen Immunotherapy based on Anergis Contiguous Overlapping Peptides (COP) linked to Virosomes will be tested by Stallergenes Greer using its therapeutic model of birch pollen allergy.

• Stallergenes Greer Will Be at 2019 EAACI Congress and Present the Results of Its Phase III House Dust Mites Tablet Trial

  5/31/2019

  Stallergenes Greer announced that house dust mite induced allergic rhinitis, its treatment with sublingual tablets and the benefits of allergen immunotherapy for patients will be presented at the annual EAACI Congress to be held in Lisbon from June 1-5 2019.

• Stallergenes Greer Announces That the Phase III Trial for Its Sublingual Allergy Immunotherapy Tablet STAGR320 to Treat House Dust Mite-Induced Allergic Rhinitis Achieved Its Primary Endpoint

  11/20/2018

  The study achieved its primary efficacy endpoint (p<0.0001)

• Stallergenes Greer Announces U.S. FDA Approval of Pediatric Indication Extension for Oralair® Sublingual Immunotherapy Tablet for the Treatment of Grass Pollen Allergy

  11/14/2018

  Stallergenes Greer today announced that it has received approval from the U.S. Food and Drug Administration (FDA) for the extension of the indication for Oralair® (Sweet Vernal, Orchard, Perennial Rye, Timothy, and Kentucky Blue Grass Mixed Pollens Allergen Extract), an allergy immunotherapy sublingual tablet, to treat patients ages five to nine with grass pollen-induced allergic rhinitis.

• Stallergenes Greer Provides Business Update and Refines Its 2018 Financial Outlook

  6/7/2018

  Company now expects 2018 net sales to be in the range of €270 million to €280 million and EBITDA to be in the range of €40 million to €50 million.

• Stallergenes Greer plc: Two New Real-World Evidence Studies Show Long-Term Benefits of Sublingual Allergy Immunotherapy

  5/29/2018

  Stallergenes Greer announced positive results from two real-world evidence studies regarding the use of allergy immunotherapy (AIT) compared to the use of only symptomatic treatments to treat patients with respiratory allergies.